Clinical trials: Pancreatic Fibrosis
Primary Ciliary Dyskinesia (PCD), Cystic Fibrosis (CF)
Clean Air for Rare MUcociliary Clearance dIsorders
The goal of this clinical trial is to learn whether using a high efficiency particulate air (HEPA) air purifier can improve respiratory health in children and adults with Cystic Fibrosis (CF) or Primary Ciliary Dyskinesia (PCD).
- Trial name
- CARMUCI (NCT07417267)
- Testing
- Intervention configuration - air purifiers equipped with HEPA and three other filters for efficient particle filtration
- Where
- Cyprus
- Volunteers
- 62 people
- Sponsor
- University of Cyprus
Cystic Fibrosis
Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients
The majority of cystic fibrosis (CF) patients die from a progressive pulmonary disease.Airway inflammation plays a major role for the pathogenesis of CF lung disease, and ultimately leads to lung destruction.
- Trial name
- NCT00506688
- Testing
- reduced glutathione sodium salt, 0.9% normal saline (control)
- Where
- 14 sites in Germany
- Volunteers
- 153 people
- Sponsor
- Mukoviszidose Institut gGmbH
Alpha-1 Antitrypsin Deficiency, AAT Deficiency
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.
- Conditions
- Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD, Cystic Fibrosis (CF)
- Trial name
- NCT01851642
- Testing
- History and physical exam., Blood draw., Pulmonary function testing.
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Florida
Cystic Fibrosis
Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
People with Cystic Fibrosis (CF) have problems digesting their food properly. More than 8 in 10 people with CF must take medication to assist their digestion. In spite of this, complications such as bowel blockage occur.
- Trial name
- GIFT-CF2 (NCT04006873)
- Testing
- Tezacaftor/Ivacaftor + Ivacaftor
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR)…
- Trial name
- ENVISION (NCT00909727)
- Testing
- Ivacaftor
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 52 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis (CF)
Progressive Muscle Relaxation in Pulmonary Rehab for Quality of Life, Mental Health, and Sleep in Cystic Fibrosis
This study, called PRIME-CF, will look at how adding progressive muscle relaxation (PMR) to a typical pulmonary rehabilitation (PR) program might help adults with cystic fibrosis (CF).
- Trial name
- PRIME-CF (NCT06592742)
- Testing
- Pulmonary rehabilitation (alone), Intervention group (PR + PMR)
- Where
- Romania
- Volunteers
- 22 people
- Sponsor
- Spitalul Clinic de Boli Infecțioase și Pneumoftiziologie Dr. Victor Babeș Timișoara
Healthy
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects
This is a first in human study of ETD002 a new drug being developed for the treatment of cystic fibrosis.The study is a randomised, double-blind, placebo-controlled, interventional study to assess the safety and tolerability of…
- Trial name
- NCT04488705
- Testing
- ETD002 - single dose, ETD002 - 7 day repeat dose, ETD002 - 14 day repeat dose
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Enterprise Therapeutics Ltd
Cystic Fibrosis (CF), Achromobacter Infection
Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection
The goal of this clinical trial is to learn if a new treatment called AchromoPhage is safe and well tolerated in adults with cystic fibrosis (CF) who have long-term lung infections caused by Achromobacter bacteria.
- Trial name
- NCT07275905
- Testing
- AchromoPhage
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ghady Haidar
Cystic Fibrosis
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for diagnosis of CF but still has a number of…
- Trial name
- NCT05998629
- Testing
- a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels, Standard of Care laboratory procedure for measurement of sweat
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis Lung
Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis
In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M.
- Trial name
- BioMol-MA (NCT06413459)
- Testing
- Luminex; scRNAsec
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Ospedale San Raffaele
Cystic Fibrosis
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
The purpose of this study is to assess the pharmacokinetics and safety of VX-809 and VX-770 alone and in combination in healthy subjects.
- Trial name
- NCT01216046
- Testing
- VX-809, VX-770
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis, Liver Disease or Abnormalities
Diagnosis and Treatment of Patients With Cystic Fibrosis
This is an omnibus protocol for studying patients with cystic fibrosis. The main purpose of the study is to obtain samples and data collected during standard clinical care for future research to expand knowledge of the natural…
- Conditions
- Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
- Trial name
- NCT00001223
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cystic Fibrosis
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
The aim of this study is to assess whether the 1 minute Sit to Stand (STS) test can be used as a measure of submaximal endurance during a pulmonary exacerbation of Cystic Fibrosis (CF) for patients in the acute care setting.
- Trial name
- NCT04058548
- Testing
- Sit to stand test
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Boston Children's Hospital
Cystic Fibrosis
LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients
In this trial, various factors that may influence the antibiotic concentrations measured in the sputum of cystic fibrosis patients are studied. A first factor is aerosol use.
- Trial name
- NCT02840136
- Testing
- Piperacillin-tazobactam combination product, Meropenem, Ceftazidime
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University Ghent
Cystic Fibrosis, Healthy
Real-Time Assessment of Lung Structure and Function in Children and Young Adults With CF Using Electrical Impedance Tomography
The purpose of this study is to determine the ability of electrical impedance tomography (EIT) to identify structural and functional physiological changes that occur with disease progression in cystic fibrosis patients.
- Trial name
- NCT05455671
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis
A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes
The study evaluates the long-term safety and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination (TC) in participants with CF who are 6 years of age and older with F/MF genotypes.
- Trial name
- NCT04545515
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 34 sites in Australia, Canada and 8 more
- Volunteers
- 120 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane…
- Trial name
- NCT06364176
- Testing
- Losartan
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Kansas Medical Center
Cystic Fibrosis
Upper Extremity Exercise Capacity, Muscle Oxygenation, Balance in Patients With Cystic Fibrosis
The primary aim of the study is to evaluate upper extremity exercise capacity, muscle oxygenation, balance and physical activity level in patients with cystic fibrosis..
- Trial name
- NCT04803643
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gazi University
Cystic Fibrosis, COVID-19
COVID-19 Antibody Responses in Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due…
- Trial name
- CAR-CF (NCT05561868)
- Where
- 2 sites in Ireland
- Volunteers
- 70 people
- Sponsor
- Children's Health Ireland
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
The primary objectives of this study are to assess the safety and efficacy of MS1819-SD vs porcine pancreatic enzyme replacement therapy (PERT) in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
- Trial name
- OPTION (NCT03746483)
- Testing
- MS1819, Porcine PERT
- Where
- 14 sites in United States, Poland
- Volunteers
- 41 people
- Sponsor
- Entero Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.